bevacizumab,cisplatin,atezolizumab,gemcitabine,pembrolizumab
roche,merck
['key,note,966', 'atezo', 'pembro', 'hcc', 'imbrave-050']
icymi: both imbrave-050 of adj atezo/bev for resected hcc and keynote-966 of 1l gem/cis/pembro statistically met their primary survival endpoints though the hrqol data suggests they don t impact patient qol over control #asco23 
GI Oncologist | Large/Small Bowel Cancer Eradicator | @SitemanCenter | @WashUOnc | Alum @MayoClinic @SIUSOM @UIowa @GrinnellCollege | Bad at Twitter | Views=Own